Consensus Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
9.18 ^USD	+5.03%		+20.31%	-8.75%

05-02	Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	MT
05-02	Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Vir Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e79b3500d3604f738a9ce157.10nsm_0C_CbDjwkhjgd0lVpau_yLXSjXUJlNboEq_4k.lQW6z583kBOQyHFj-jYt2SNvjc3xE367fckEFNZArNruJoPYtXC2Sff5XA~476d9cf8753de7bd7424f0f8e5514120

Analyst Recommendations on Vir Biotechnology, Inc.

HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating	02-14	MT
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23	01-29	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Cuts Price Target to $14 From $23 After Shares Underperformance	08/09/23	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Adjusts Price Target to $14 From $23	08/09/23	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $95 From $100, Keeps Buy Rating	07/08/23	MT
JPMorgan Cuts Vir Biotechnology's Price Target to $24 From $34, Maintains Overweight Rating	21/07/23	MT
Goldman Sachs Adjusts Vir Biotechnology's Price Target to $28 From $51, Keeps Buy Rating	21/07/23	MT
Barclays Adjusts Price Target on Vir Biotechnology to $41 From $59, Maintains Overweight Rating	21/07/23	MT
Morgan Stanley Cuts Vir Biotechnology's Price Target to $15 From $27, Maintains Equalweight Rating	20/07/23	MT
Needham Cuts Vir Biotechnology's Price Target to $22 From $32, Maintains Buy Rating	20/07/23	MT
Morgan Stanley Adjusts Price Target on Vir Biotechnology to $27 From $25, Maintains Equal-Weight Rating	04/04/23	MT
JPMorgan Upgrades Vir Biotechnology to Overweight From Neutral, Adjusts Price Target to $34 From $35	06/03/23	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $100 From $125, Keeps Buy Rating	06/03/23	MT
Goldman Sachs Upgrades Vir Biotechnology to Buy From Neutral, Adjusts Price Target to $53 From $41	21/02/23	MT
Morgan Stanley Upgrades Vir Biotechnology to Equal Weight From Underweight, Adjusts Price Target to $30 From $18	27/01/23	MT
SVB Securities Adjusts Vir Biotechnology's Price Target to $43 From $45, Maintains Outperform Rating	27/01/23	MT
Needham Adjusts Price Target on Vir Biotechnology to $32 From $35, Maintains Buy Rating	04/11/22	MT
SVB Securities Starts Vir Biotechnology at Outperform With $40 Price Target	14/09/22	MT
Morgan Stanley Initiates Vir Biotechnology at Underweight With $15 Price Target	09/09/22	MT
HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy Rating	12/05/22	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Buy Rating	30/03/22	MT
Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating	28/03/22	MT
Baird Upgrades Vir Biotechnology to Neutral From Underperform, Adjusts Price Target to $28 From $36	03/03/22	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $300 from $200, Keeps Buy Rating	21/12/21	MT
Baird Downgrades Vir Biotechnology to Underperform From Neutral; Price Target is $36	21/12/21	MT